(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 September 2023 (14.09.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/172906 A1

(51) International Patent Classification:
A61K 47/68 (2017.01) *A61P 35/00* (2006.01)
A61K 39/00 (2006.01)

(21) International Application Number:
PCT/US2023/063852

(22) International Filing Date:
07 March 2023 (07.03.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/317,472 07 March 2022 (07.03.2022) US
63/329,680 11 April 2022 (11.04.2022) US

(71) Applicant: **MERSANA THERAPEUTICS, INC.** [US/US]; 840 Memorial Drive, Cambridge, Massachusetts 02139 (US).

(72) Inventors: **BUKHALID, Raghida A.**; 150 Rivers Edge Drive, Apt. 390, Medford, Massachusetts 02155 (US). **CETINBAS, Naniye**; 249 Third Street, Apt. 404, Cambridge, Massachusetts 02138 (US). **DAMELIN, Marc I.**; 42 Lexington Avenue, Needham, Massachusetts 02494 (US). **LOWINGER, Timothy B.**; 352 School Street, Carlisle, Massachusetts 01741 (US). **TOADER, Dorin**; 1699 Cambridge Street, Apt. 32, Cambridge, Massachusetts 02138 (US).

(74) Agent: **KOZAKIEWICZ, Cynthia A.** et al.; Cooley LLP, 1299 Pennsylvania Ave, NW, Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTS, COMBINATIONS AND METHODS OF USE

FIG. 1



(57) Abstract: The present disclosure provides combinations comprising HER2-targeted STING agonist antibody-drug conjugates and HER2-targeted therapies or immunotherapies. The present disclosure also provides uses of the combinations in treatment, e.g., treatment of cancer.

WO 2023/172906 A1

[Continued on next page]

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*